Literature DB >> 23200096

Cardiovascular pharmacogenomics: the future of cardiovascular therapeutics?

Dan M Roden1.   

Abstract

Responses to drug therapy vary from benefit to no effect to adverse effects which can be serious or occasionally fatal. Increasing evidence supports the idea that genetic variants can play a major role in this spectrum of responses. Well-studied examples in cardiovascular therapeutics include predictors of steady-state warfarin dosage, predictors of reduced efficacy among patients receiving clopidogrel for drug eluting stents, and predictors of some serious adverse drug effects. This review summarizes contemporary approaches to identifying and validating genetic predictors of variability in response to drug treatment. Approaches to incorporating this new knowledge into clinical care, and the barriers to this concept, are addressed.
Copyright © 2013 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23200096      PMCID： PMC3529768          DOI： 10.1016/j.cjca.2012.07.845

Source DB:  PubMed          Journal:  Can J Cardiol        ISSN： 0828-282X            Impact factor:   5.223


  83 in total

Review 1.  Genomewide association studies and assessment of the risk of disease.

Authors:  Teri A Manolio
Journal:  N Engl J Med       Date:  2010-07-08       Impact factor: 91.245

2.  HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans.

Authors:  Mark McCormack; Ana Alfirevic; Stephane Bourgeois; John J Farrell; Dalia Kasperavičiūtė; Mary Carrington; Graeme J Sills; Tony Marson; Xiaoming Jia; Paul I W de Bakker; Krishna Chinthapalli; Mariam Molokhia; Michael R Johnson; Gerard D O'Connor; Elijah Chaila; Saud Alhusaini; Kevin V Shianna; Rodney A Radtke; Erin L Heinzen; Nicole Walley; Massimo Pandolfo; Werner Pichler; B Kevin Park; Chantal Depondt; Sanjay M Sisodiya; David B Goldstein; Panos Deloukas; Norman Delanty; Gianpiero L Cavalleri; Munir Pirmohamed
Journal:  N Engl J Med       Date:  2011-03-24       Impact factor: 91.245

3.  Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis.

Authors:  Jessica L Mega; Tabassome Simon; Jean-Philippe Collet; Jeffrey L Anderson; Elliott M Antman; Kevin Bliden; Christopher P Cannon; Nicolas Danchin; Betti Giusti; Paul Gurbel; Benjamin D Horne; Jean-Sebastian Hulot; Adnan Kastrati; Gilles Montalescot; Franz-Josef Neumann; Lei Shen; Dirk Sibbing; P Gabriel Steg; Dietmar Trenk; Stephen D Wiviott; Marc S Sabatine
Journal:  JAMA       Date:  2010-10-27       Impact factor: 56.272

4.  Charting a course for genomic medicine from base pairs to bedside.

Authors:  Eric D Green; Mark S Guyer
Journal:  Nature       Date:  2011-02-10       Impact factor: 49.962

Review 5.  The phenotype standardization project: improving pharmacogenetic studies of serious adverse drug reactions.

Authors:  M Pirmohamed; G P Aithal; E Behr; A Daly; D Roden
Journal:  Clin Pharmacol Ther       Date:  2011-06       Impact factor: 6.875

6.  A common β1-adrenergic receptor polymorphism predicts favorable response to rate-control therapy in atrial fibrillation.

Authors:  Babar Parvez; Nagesh Chopra; Shane Rowan; Joseph C Vaglio; Raafia Muhammad; Dan M Roden; Dawood Darbar
Journal:  J Am Coll Cardiol       Date:  2012-01-03       Impact factor: 24.094

7.  Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan.

Authors:  Pei Chen; Juei-Jueng Lin; Chin-Song Lu; Cheung-Ter Ong; Peiyuan F Hsieh; Chih-Chao Yang; Chih-Ta Tai; Shey-Lin Wu; Cheng-Hsien Lu; Yung-Chu Hsu; Hsiang-Yu Yu; Long-Sun Ro; Chung-Ta Lu; Chun-Che Chu; Jing-Jane Tsai; Yu-Hsiang Su; Sheng-Hsing Lan; Sheng-Feng Sung; Shu-Yi Lin; Hui-Ping Chuang; Li-Chen Huang; Ying-Ju Chen; Pei-Joung Tsai; Hung-Ting Liao; Yu-Hsuan Lin; Chien-Hsiun Chen; Wen-Hung Chung; Shuen-Iu Hung; Jer-Yuarn Wu; Chi-Feng Chang; Luke Chen; Yuan-Tsong Chen; Chen-Yang Shen
Journal:  N Engl J Med       Date:  2011-03-24       Impact factor: 91.245

8.  The eMERGE Network: a consortium of biorepositories linked to electronic medical records data for conducting genomic studies.

Authors:  Catherine A McCarty; Rex L Chisholm; Christopher G Chute; Iftikhar J Kullo; Gail P Jarvik; Eric B Larson; Rongling Li; Daniel R Masys; Marylyn D Ritchie; Dan M Roden; Jeffery P Struewing; Wendy A Wolf
Journal:  BMC Med Genomics       Date:  2011-01-26       Impact factor: 3.063

9.  Statistical design of personalized medicine interventions: the Clarification of Optimal Anticoagulation through Genetics (COAG) trial.

Authors:  Benjamin French; Jungnam Joo; Nancy L Geller; Stephen E Kimmel; Yves Rosenberg; Jeffrey L Anderson; Brian F Gage; Julie A Johnson; Jonas H Ellenberg
Journal:  Trials       Date:  2010-11-17       Impact factor: 2.279

10.  9p21 DNA variants associated with coronary artery disease impair interferon-γ signalling response.

Authors:  Olivier Harismendy; Dimple Notani; Xiaoyuan Song; Nazli G Rahim; Bogdan Tanasa; Nathaniel Heintzman; Bing Ren; Xiang-Dong Fu; Eric J Topol; Michael G Rosenfeld; Kelly A Frazer
Journal:  Nature       Date:  2011-02-10       Impact factor: 49.962
View more
  3 in total

Review 1.  The genetics of pro-arrhythmic adverse drug reactions.

Authors:  Evmorfia Petropoulou; Yalda Jamshidi; Elijah R Behr
Journal:  Br J Clin Pharmacol       Date:  2014-04       Impact factor: 4.335

2.  Feasibility of clinical pharmacist-led CYP2C19 genotyping for patients receiving non-emergent cardiac catheterization in an integrated health system.

Authors:  Samuel G Johnson; Paul B Shaw; Thomas Delate; Deanna L Kurz; Dylon Gregg; John C Darnell; Christina L Aquilante
Journal:  Pharm Pract (Granada)       Date:  2017-06-30

3.  A synergic effect between CYP2C19*2, CYP2C19*3 loss-of-function and CYP2C19*17 gain-of-function alleles is associated with Clopidogrel resistance among Moroccan Acute Coronary Syndromes patients.

Authors:  Hind Hassani Idrissi; Wiam Hmimech; Nada El Khorb; Hafid Akoudad; Rachida Habbal; Sellama Nadifi
Journal:  BMC Res Notes       Date:  2018-01-18
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.